HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Hoth Therapeutics (NASDAQ:HOTH) and maintained a price target of $4.
July 26, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Hoth Therapeutics and maintained a price target of $4.
The reiteration of a Buy rating and the maintenance of a $4 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100